Logo
x

Search

Subscribe Now

asthma

Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma

Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-...

  • October 21, 2021
AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III MANDALA and DENALI Trials for the Treatment of Asthma

AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III MANDALA and DENALI Trials for the Treatment of Asthma

  • September 9, 2021
AstraZeneca Presents Results of Fasenra in P-IIIb PONENTE Study for the Treatment of Asthma at ERS 2021

AstraZeneca Presents Results of Fasenra in P-IIIb PONENTE Study for the Treatment of Asthma at ERS 2021

  • September 8, 2021
AstraZeneca and Amgen's Tezepelumab Demonstrates 86% Reduction in Exacerbations in Patients with Asthma and Nasal Polyps

AstraZeneca and Amgen's Tezepelumab Demonstrates 86% Reduction in Exacerbations in Patients with Asthma and Nasal Polyps

  • September 6, 2021
AstraZeneca and Amgen Report the US FDA's Acceptance of BLA and Priority Review of Tezepelumab for the Treatment of Asthma

AstraZeneca and Amgen Report the US FDA's Acceptance of BLA and Priority Review of Tezepelumab for the Treatment of Asthma

  • July 8, 2021
CytoReason Collaborates with Sanofi to Initiate its Project Utilizing AI Technology for Asthma

CytoReason Collaborates with Sanofi to Initiate its Project Utilizing AI Technology for Asthma

  • June 18, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.